Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer. Using whole-exome sequencing and in silico neoantigen prediction, we found that tumours with both the highest neoantigen number and the most abundant CD8+ T-cell infiltrates, but neither alone, stratified patients with the longest survival. Investigating the specific neoantigen qualities promoting T-cell activation in long-term survivors, we discovered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as CA125). A neoantigen quality fitness model conferring greater immunogenicity to neoantigens with differential presentation and homology to infectious disease-derived peptides identified long-term survivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did not. We detected intratumoural and lasting circulating T-cell reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones with specificity to both high-quality neoantigens and predicted cross-reactive microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we observed selective loss of high-quality and MUC16 neoantigenic clones on metastatic progression, suggesting neoantigen immunoediting. Our results identify neoantigens with unique qualities as T-cell targets in pancreatic ductal adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for immunogenic tumours that may guide the application of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In rare patients with localized PDAC who are long-term survivors, bacteria can translocate from the intestine into the tumour and control anti-tumour immune activation11,12.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [12]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, the gut microbiota can indirectly increase the immunogenicity of tumor cells by providing tumor cross-antigens to promote the efficacy of ICI [50, 68, 69].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PDAC tumors from long term survivors have high quantity and quality of neoantigens, and stronger infiltration and activation of CD8+ T cells”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that microbial host factors, independent of the genomic composition of the tumor, may determine tumor behavior and patient outcomes.”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Significantly, the aggressive progression of PDAC, characterized by immune evasion and therapeutic resistance, is heavily influenced by the TME (Balachandran et al., 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Cited by
Items 301–400 of 1,001
Immuno-oncology-101: overview of major concepts and translational perspectives
Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 68
Lorkowski, M. E., Atukorale, P. U., Bielecki, P. A., Tong, K.-K., Covarrubias, G., Zhang, Y., Loutrianakis, G., Moon, T. J., Santulli, A. R., Becicka, W. M., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.014 · Cited by 60
Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy
Sidhom, J.-W., Oliveira, G., Ross-MacDonald, P., Wind-Rotolo, M., Wu, C. J., Pardoll, D. M., & Baras, A. S. (2022) · Science Advances · doi:10.1126/sciadv.abq5089 · Cited by 57
The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells
Cheng, H., Ma, K., Zhang, L., & Li, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.013 · Cited by 65
Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
Li, X., Gulati, M., Larson, A. C., Solheim, J. C., Jain, M., Kumar, S., & Batra, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.009 · Cited by 59
Zou, X., Lin, X., Cheng, H., Chen, Y., Wang, R., Ma, M., Liu, Y., Dai, Z., Tasiheng, Y., Yan, Y., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006698 · Cited by 71
Advances in mRNA-Based Cancer Vaccines
Ni, L. (2023) · Vaccines · doi:10.3390/vaccines11101599 · Cited by 62
Shima, H., Tsurita, G., Wada, S., Hirohashi, Y., Yasui, H., Hayashi, H., Miyakoshi, T., Watanabe, K., Murai, A., Asanuma, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14106 · Cited by 60
Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer
Kemp, S. B., Pasca di Magliano, M., & Crawford, H. C. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.006 · Cited by 55
Computational cancer neoantigen prediction: current status and recent advances
Fotakis, G., Trajanoski, Z., & Rieder, D. (2021) · Immuno-Oncology and Technology · doi:10.1016/j.iotech.2021.100052 · Cited by 54
Gajiwala, S., Torgeson, A. M., Garrido‐Laguna, I., Kinsey, C. G., & Lloyd, S. A. J. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.05.16 · Cited by 56
Potential links between the microbiota and T cell immunity determine the tumor cell fate
Mohseni, A. H., Taghinezhad‐S, S., Casolaro, V., Lv, Z., & Li, D. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05560-2 · Cited by 55
The gut dysbiosis-cancer axis: illuminating novel insights and implications for clinical practice
Asseri, A. H., Bakhsh, T., Abuzahrah, S. S., Ali, S., & Rather, I. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1208044 · Cited by 61
Huber, F., & Bassani‐Sternberg, M. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01208-8 · Cited by 64
Rai, Z. L., Feakins, R. M., Pallett, L. J., Manas, D., & Davidson, B. R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081609 · Cited by 60
Effern, M., Glodde, N., Braun, M., Liebing, J., Boll, H. N., Yong, M. C. R., Bawden, E., Hinze, D., Konijnenberg, D., Daoud, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.007 · Cited by 58
Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
Schmiechen, Z. C., & Stromnes, I. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613815 · Cited by 68
Anagnostou, V., Landon, B. V., Medina, J. E., Forde, P. M., & Velculescu, V. E. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3958 · Cited by 54
Meng, Z., Rodriguez-Ehrenfried, A., Tan, C. L., Steffens, L. K., Kehm, H., Zens, S., Lauenstein, C., Paul, A., Schwab, M., Förster, J. D., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh9562 · Cited by 58
Parkin, A., Man, J., Timpson, P., & Pajic, M. (2019) · FEBS Journal · doi:10.1111/febs.15011 · Cited by 58
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
Shembrey, C., Huntington, N. D., & Hollande, F. (2019) · Cancers · doi:10.3390/cancers11091217 · Cited by 56
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23179 · Cited by 63
Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Boesch, M., Baty, F., Rothschild, S. I., Tamm, M., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01365-2 · Cited by 58
Zhou, Z., Zhang, J., Xu, C., Yang, J., Zhang, Y., Liu, M., Shi, X., Li, X., Zhan, H., Chen, W., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103271 · Cited by 60
Self-citationBiomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Engineering neoantigen vaccines to improve cancer personalized immunotherapy
Liu, Z., Lv, J., Dang, Q., Liu, L., Weng, S., Wang, L., Zhou, Z., Kong, Y., Li, H., Han, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.76281 · Cited by 58
Intratumoral bacteria are an important “accomplice” in tumor development and metastasis
Wang, G., He, X., & Wang, Q. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188846 · Cited by 52
Koumantou, D., Barnea, E., Martín‐Esteban, A., Maben, Z., Papakyriakou, A., Mpakali, A., Kokkala, P., Pratsinis, H., Georgiadis, D., Stern, L. J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02358-0 · Cited by 55
Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy
Aktar, N., Yueting, C., Abbas, M., Zafar, H., Paiva‐Santos, A. C., Zhang, Q., Chen, T., Ahmed, M., Raza, F., & Zhou, X. (2022) · Journal of Oncology · doi:10.1155/2022/8901326 · Cited by 63
Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer
Zhang, J., Wolfgang, C. L., & Zheng, L. (2018) · Cancers · doi:10.3390/cancers10020039 · Cited by 57
Self-citationMHCquant: Automated and Reproducible Data Analysis for Immunopeptidomics
Bichmann, L., Nelde, A., Ghosh, M., Heumos, L., Mohr, C., Peltzer, A., Kuchenbecker, L., Sachsenberg, T., Walz, J. S., Stevanović, S., et al. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00313 · Cited by 56
Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy
Richard, G., Princiotta, M. F., Bridon, D. P., Martin, W. D., Steinberg, G. D., & Groot, A. S. D. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2012456 · Cited by 53
D’Alise, A. M., Leoni, G., Cotugno, G., Siani, L., Vitale, R. L., Ruzza, V., Garzia, I., Antonucci, L., Micarelli, E., Venafra, V., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3940 · Cited by 55
Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer
Ali, A. I., Oliver, A. J., Samiei, T., Chan, J. D., Kershaw, M. H., & Slaney, C. Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00056 · Cited by 50
Novel Biomarkers for Personalized Cancer Immunotherapy
Shindo, Y., Hazama, S., Tsunedomi, R., Suzuki, N., & Nagano, H. (2019) · Cancers · doi:10.3390/cancers11091223 · Cited by 52
Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer
Vonderheide, R. H., & Bear, A. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.605619 · Cited by 56
Zhang, W., Shi, F., Kong, Y., Li, Y., Sheng, C., Wang, S., & Wang, Q. (2021) · Cancer Medicine · doi:10.1002/cam4.4472 · Cited by 61
Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184351 · Cited by 53
Challenges towards the realization of individualized cancer vaccines
Türeci, Ö., Löwer, M., Schrörs, B., Lang, M., Tadmor, A. D., & Şahin, U. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0266-2 · Cited by 51
Mauriello, A., Zeuli, R., Cavalluzzo, B., Petrizzo, A., Tornesello, M. L., Buonaguro, L., Ceccarelli, M., Tagliamonte, M., & Buonaguro, L. (2019) · Cancers · doi:10.3390/cancers11121824 · Cited by 53
Lu, T., Wang, S., Xu, L., Zhou, Q., Singla, N., Gao, J., Manna, S., Pop, L., Xie, Z., Chen, M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz3199 · Cited by 48
Progress in Neoantigen Targeted Cancer Immunotherapies
Han, X.-J., Ma, X.-L., Yang, L., Wei, Y.-Q., Peng, Y., & Wei, X.-W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00728 · Cited by 47
Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression
Hussain, S. M., Kansal, R. G., Alvarez, M. A., Hollingsworth, T., Elahi, A. H., Miranda‐Carboni, G. A., Hendrick, L. E., Pingili, A. K., Albritton, L. M., Dickson, P. V., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00594-0 · Cited by 49
Sadozai, H., Acharjee, A., Eppenberger‐Castori, S., Gloor, B., Gruber, T., Schenk, M., & Karamitopoulou, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643529 · Cited by 55
PD-1 inhibition in advanced myeloproliferative neoplasms
Hobbs, G. S., Bozkus, C. C., Moshier, E. L., Dougherty, M., Bar‐Natan, M., Sandy, L., Johnson, K. L., Foster, J., Som, T. T., Macrae, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005491 · Cited by 51
Tumor-Specific CD4 T Cells Instruct Monocyte Differentiation in Pancreatic Ductal Adenocarcinoma
Patterson, M. T., Burrack, A. L., Xu, Y., Hickok, G. H., Schmiechen, Z. C., Becker, S., Cruz-Hinojoza, E., Schrank, P. R., Kennedy, A. E., Firulyova, M. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2023.112732 · Cited by 51
Lu, S., Wang, C., Ma, J., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456030 · Cited by 56
Gao, Y., Tan, Y.-J., & Fang, J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01026-w · Cited by 55
A myeloid and lymphoid infiltrate in murine pancreatic tumors exposed to plasma-treated medium
Liedtke, K. R., Freund, E., Hackbarth, C., Heidecke, C.-D., Partecke, L.-I., & Bekeschus, S. (2018) · Clinical Plasma Medicine · doi:10.1016/j.cpme.2018.07.001 · Cited by 48
Epithelial-Stromal Interactions in Pancreatic Cancer
Zhang, Y., Crawford, H. C., & Pasca di Magliano, M. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114515 · Cited by 49
Lippman, S. M., Abate-Shen, C. T., Maresso, K. C., Colditz, G. A., Dannenberg, A. J., Davidson, N. E., Disis, M. L., DuBois, R. N., Szabo, E. M., Giuliano, A. R., et al. (2018) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-18-0421 · Cited by 52
Pancreatic Cancer Detection in Whole Slide Images Using Noisy Label Annotations
Le, H., Samaras, D., Kurç, T., Gupta, R., Shroyer, K. R., & Saltz, J. H. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-32239-7_60 · Cited by 56
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal
Bianchi, V., Harari, A., & Coukos, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01215 · Cited by 49
Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients
Petrizzo, A., Tagliamonte, M., Mauriello, A., Costa, V., Aprile, M., Esposito, R., Caporale, A., Luciano, A., Arra, C., Tornesello, M. L., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1662-9 · Cited by 48
Neoantigens in Hematologic Malignancies
Biernacki, M. A., & Bleakley, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00121 · Cited by 50
Bouzid, R., Peppelenbosch, M. P., & Buschow, S. I. (2020) · Cancers · doi:10.3390/cancers12051121 · Cited by 52
Wang, G., Wan, H., Jian, X., Li, Y., Ouyang, J., Tan, X., Zhao, Y., Lin, Y., & Xie, L. (2020) · BioMed Research International · doi:10.1155/2020/5798356 · Cited by 52
Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations
Chen, Z., Zhang, S., Dong, S., Xu, H., & Zhou, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844401 · Cited by 44
Long, N. P., Jung, K. H., Anh, N. H., YAN, H. H., Nghi, T. D., Park, S., Yoon, S. J., Min, J. E., Kim, H. M., Lim, J. H., et al. (2019) · Cancers · doi:10.3390/cancers11020155 · Cited by 49
Sui, M., Li, Y., Wang, H., Luo, Y., Wan, T. Y., Wang, X., Hu, B., Cheng, Y., Lv, X., Xin, X., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0596-y · Cited by 47
Next-Generation Sequencing in Pancreatic Cancer
Shen, G.-Q., Aleassa, E. M., Walsh, R. M., & Morris‐Stiff, G. J. (2019) · Pancreas · doi:10.1097/mpa.0000000000001324 · Cited by 49
Yang, H., Sun, L., Guan, A., Yin, H., Liu, M., Mao, X., Xu, H. C., Zhao, H., Lü, X., Sang, X., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02711-8 · Cited by 50
Chen, Y., Wang, C., Song, J., Xu, R., Ruze, R., & Zhao, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.758004 · Cited by 51
Extracellular vesicles in pancreatic cancer immune escape: Emerging roles and mechanisms
Liu, C., He, D., Li, L., Zhang, S., Wang, L., Fan, Z., & Wang, Y. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106364 · Cited by 46
Liffers, S., Godfrey, L., Frohn, L., Häberle, L., Yavas, A., Vesce, R., Goering, W., Opitz, F. V., Stoecklein, N. H., Knoefel, W. T., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326550 · Cited by 55
The Role of the Microbiome in Pancreatic Cancer
Miyabayashi, K., Ijichi, H., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184479 · Cited by 53
Link, J. M., Eng, J. R., Pelz, C., Hawthorne, K., Worth, P. J., Sivagnanam, S., Keith, D., Owen, S., Langer, E. M., Grossblatt-Wait, A., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00881-3 · Cited by 49
Jentzsch, V., Davis, J., & Djamgoz, M. B. A. (2020) · Cancers · doi:10.3390/cancers12113096 · Cited by 46
Bioinformatic methods for cancer neoantigen prediction
Boegel, S., Castle, J. C., Kodysh, J., O'Donnell, T., & Rubinsteyn, A. (2019) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2019.06.016 · Cited by 44
Bouchart, C., Navez, J., Closset, J., Hendlisz, A., Gestel, D. V., Moretti, L., & Laethem, J. V. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936093 · Cited by 44
T-Cell Immunity in Pancreatic Cancer
Ajina, R., & Weiner, L. M. (2020) · Pancreas · doi:10.1097/mpa.0000000000001621 · Cited by 50
Jiang, P., Yang, F., Zou, C., Bao, T., Wu, M., Yang, D., & Bu, S. (2021) · Aging · doi:10.18632/aging.202801 · Cited by 50
Liao, J.-Y., & Zhang, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.663264 · Cited by 48
Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth
Aurisicchio, L., Salvatori, E., Lione, L., Bandini, S., Pallocca, M., Maggio, R., Fanciulli, M., Nicola, F. D., Goeman, F., Ciliberto, G., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1084-4 · Cited by 45
Peskov, K. V., Azarov, I., Chu, L., Voronova, V., Kosinsky, Y., & Helmlinger, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00924 · Cited by 43
Precision medicine in pancreatic cancer: treating every patient as an exception
Herbst, B. T., & Zheng, L. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30175-x · Cited by 47
Self-citationTackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches
Tagliamonte, M., Mauriello, A., Cavalluzzo, B., Ragone, C., Manolio, C., Petrizzo, A., & Buonaguro, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.029 · Cited by 45
Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis
Thomas, S. K., Lee, J., & Beatty, G. L. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102662 · Cited by 47
Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective
Wang, C., Yu, M., & Zhang, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215945 · Cited by 43
Karamitopoulou, E., Wenning, A. S., Acharjee, A., Zlobec, I., Aeschbacher, P., Perren, A. A., & Gloor, B. (2023) · Gut · doi:10.1136/gutjnl-2022-329371 · Cited by 44
Katz, M. H. G., Petroni, G. R., Bauer, T. W., Reilley, M. J., Wolpin, B. M., Stucky, C., Bekaii‐Saab, T., Elias, R., Merchant, N. B., Costa, A. D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007586 · Cited by 41
CD4 T cell–activating neoantigens enhance personalized cancer vaccine efficacy
Huff, A. L., Longway, G., Mitchell, J. T., Andaloori, L., Davis-Marcisak, E. F., Chen, F., Lyman, M. R., Wang, R., Mathew, J., Barrett, B., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.174027 · Cited by 46
Li, X., Xu, H., Li, C., Qiao, G., Farooqı, A. A., Gedanken, A., Liu, X., & Lin, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00319 · Cited by 43
Yu, Y., Yang, G., Huang, H., Fu, Z., Cao, Z., Zheng, L., You, L., & Zhang, T. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01787-5 · Cited by 49
Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu, Y., Biswas, D., & Swanton, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.013 · Cited by 47
Next-Generation Digital Histopathology of the Tumor Microenvironment
Mungenast, F., Fernando, A., Nica, R., Boghiu, B., Lungu, B., Batra, J., & Ecker, R. (2021) · Genes · doi:10.3390/genes12040538 · Cited by 48
Neoantigens elicit T cell responses in breast cancer
Morisaki, T., Kubo, M., Umebayashi, M., Yew, P. Y., Yoshimura, S., Park, J.-H., Kiyotani, K., Kai, M., Yamada, M., Oda, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91358-1 · Cited by 46
Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
Zheng, Y., Fu, Y., Wang, P., & Ding, Z. (2022) · Disease Markers · doi:10.1155/2022/8270305 · Cited by 43
Identifying neoantigens for use in immunotherapy
Hutchison, S., & Pritchard, A. L. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9771-6 · Cited by 43
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40
“In humans, long-term survival in pancreatic cancer was associated with the development of highly immunogenic neoantigens with predicted cross-reactivity tomicrobial epitopes (69).”
BackgroundPollini, T., Adsay, V., Capurso, G., Molin, M. D., Esposito, I., Hruban, R. H., Luchini, C., Maggino, L., Matthaei, H., Marchegiani, G., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00235-7 · Cited by 44
Unveiling the intratumoral microbiota within cancer landscapes
Che, S., Yan, Z., Feng, Y., & Hai, Z. (2024) · iScience · doi:10.1016/j.isci.2024.109893 · Cited by 44
Recent progress in cancer vaccines and nanovaccines
Poudel, K., Vithiananthan, T., Kim, J. O., & Tsao, H. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122856 · Cited by 43
Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
Garces, A. I., Au, L., Mason, R., Thomas, J. M., & Larkin, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1649657 · Cited by 42
IEAtlas: an atlas of HLA-presented immune epitopes derived from non-coding regions
Cai, Y., Lv, D., Li, D., Yin, J., Ma, Y., Luo, Y. H., Fu, L., Ding, N., Li, Y., Pan, Z., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac776 · Cited by 41
The intratumoral microbiota: friend or foe?
Ferrari, V., & Rescigno, M. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.03.005 · Cited by 46
Hu, J., & Sun, J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1487914 · Cited by 39
Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma
Chiaro, J., Kasanen, H. H. E., Whalley, T., Capasso, C., Grönholm, M., Feola, S., Peltonen, K., Hamdan, F., Hernberg, M., Mäkelä, S., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0814 · Cited by 42
Neoantigens in precision cancer immunotherapy: from identification to clinical applications
Zhang, Q., Jia, Q., Zhang, J., & Zhu, B. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002181 · Cited by 44
Self-citationTargeting dendritic cells in pancreatic ductal adenocarcinoma
Deicher, A., Andersson, R. E., Tingstedt, B., Lindell, G., Bauden, M. P., & Ansari, D. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0585-0 · Cited by 38
Metadata
- Authors
- Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., Wells, D. K., Cary, C. I. O., Grbovic-Huezo, O., Attiyeh, M., Medina, B., Zhang, J., Loo, J., Saglimbeni, J., Abu-Akeel, M., Zappasodi, R., Riaz, N., Smoragiewicz, M., Kelley, Z. L., Basturk, O., Gönen, M., Levine, A. J., Allen, P. J., Fearon, D. T., Merad, M., Gnjatic, S., Iacobuzio-Donahue, C. A., Wolchok, J. D., DeMatteo, R. P., Chan, T. A., Greenbaum, B. D., Merghoub, T., & Leach, S. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Swim Across America (US)
- University of Cambridge (GB)
- Cold Spring Harbor Laboratory (US)
- Corresponding author
- Balachandran, Vinod P.
- ORCID
- Balachandran, Vinod P.
- Łuksza, Marta
- Zhao, Julia N.
- Makarov, Vladimir
- Herbst, Brian
- Bhanot, Umesh
- Wells, Daniel K.
- Grbovic-Huezo, Olivera
- Attiyeh, Marc
- Medina, Benjamin
- Zappasodi, Roberta
- Riaz, Nadeem
- Smoragiewicz, Martin
- Gönen, Mithat
- Levine, Arnold J.
- Fearon, Douglas T.
- Gnjatic, Sacha
- Wolchok, Jedd D.
- DeMatteo, Ronald P.
- Chan, Timothy A.
- Greenbaum, Benjamin D.
- Merghoub, Taha
- Leach, Steven D.
- Venue
- Nature
- Published
- 2017-11
- Volume
- 551
- Issue
- 7681
- Pages
- 512-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6145146
- OpenAlex
- W2767699537
- Cited by
- 1,191
- References
- 28
- Citations by year
- 2026: 89 · 2025: 114 · 2024: 119 · 2023: 178 · 2022: 169 · 2021: 153 · 2020: 135 · 2019: 132 · 2018: 94 · 2017: 6
- FWCI
- 44.60
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263, 15678)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Agence Nationale de la Recherche (ANR-18-CE14-0005)
- National Institutes of Health
- National Cancer Institute (P01CA087497, P30-CA-08748, R01CA190400, P30CA008748, T32CA009501, K12CA184746)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097087)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pancreatic ductal adenocarcinoma, long-term survival, neoantigens, CA125, CD8+ T cells, T cell immunity, immunogenicity, mutational burden, immune evasion
- MeSH terms
- Cancer Survivors, Exome Sequencing, Adenocarcinoma, Antigens, Neoplasm, Bacterial Proteins, Computer Simulation, Cross Reactions, Humans, Immunotherapy, Membrane Proteins, Pancreatic Neoplasms, Prognosis, T-Lymphocytes, Cytotoxic, Survival Analysis, CA-125 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.